Diabetic Retinopathy

Eyenuk Secures the First European Union MDR Certification for Autonomous AI Detection of Diabetic Retinopathy, Age-Related Macular Degeneration, and Glaucoma

The approval allows Eyenuk’s AI eye screening system, already approved for detection of diabetic retinopathy, to aid millions of additional patients at risk for vision loss LOS ANGELES, January 31,

Eyenuk Secures the First European Union MDR Certification for Autonomous AI Detection of Diabetic Retinopathy, Age-Related Macular Degeneration, and Glaucoma Read More »

Study Finds Eyenuk Artificial Intelligence Detects Diabetic Retinopathy with Far Greater Sensitivity than Ophthalmologists’ Dilated Exams

Academic leaders will review their experience with the technology during a symposium at AAO 2022, the American Academy of Ophthalmology annual meeting CHICAGO, September 30, 2022 — From the American

Study Finds Eyenuk Artificial Intelligence Detects Diabetic Retinopathy with Far Greater Sensitivity than Ophthalmologists’ Dilated Exams Read More »

UK National Screening Committee Report Singles Out Eyenuk’s EyeArt as the Only Diabetic Eye Screening AI Technology Ready for Live Clinical Implementation in the National Health Service

LOS ANGELES, June 1, 2022 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™ and AI

UK National Screening Committee Report Singles Out Eyenuk’s EyeArt as the Only Diabetic Eye Screening AI Technology Ready for Live Clinical Implementation in the National Health Service Read More »

Largest Peer-Reviewed Study on AI in Health Care Shows Real-World Significance of EyeArt AI Eye Screening System from Eyenuk

Landmark Study of Over 100,000 Diabetes Patient Visits Published in the Journal Diabetes Technology and Therapeutics Validates the Prowess of the EyeArt AI System for Diabetic Retinopathy Screening LOS ANGELES,

Largest Peer-Reviewed Study on AI in Health Care Shows Real-World Significance of EyeArt AI Eye Screening System from Eyenuk Read More »

EyeArt® Study Results on Patient Compliance and Screening Efficacy Improvement in Diabetic Retinopathy Screening Presented at ADA 2019

LOS ANGELES, June 5, 2019 – Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today

EyeArt® Study Results on Patient Compliance and Screening Efficacy Improvement in Diabetic Retinopathy Screening Presented at ADA 2019 Read More »

German Diabetes Clinic Increases Diabetic Retinopathy Screenings Provided from Zero to Thousands After Implementing Eyenuk’s EyeArt AI Eye Screening System

LOS ANGELES, CA, May 16, 2019 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced

German Diabetes Clinic Increases Diabetic Retinopathy Screenings Provided from Zero to Thousands After Implementing Eyenuk’s EyeArt AI Eye Screening System Read More »

Eyenuk’s AI Eye Screening System for Diabetic Retinopathy Demonstrates Exceptional Performance in a Prospective, Multi-Center, Pivotal Clinical Trial

LOS ANGELES, Calif., April 28, 2019 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced

Eyenuk’s AI Eye Screening System for Diabetic Retinopathy Demonstrates Exceptional Performance in a Prospective, Multi-Center, Pivotal Clinical Trial Read More »